76.30
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ILMN Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$76.25
Aprire:
$76.75
Volume 24 ore:
79,984
Relative Volume:
0.03
Capitalizzazione di mercato:
$11.64B
Reddito:
$4.39B
Utile/perdita netta:
$-1.58B
Rapporto P/E:
-7.6606
EPS:
-9.96
Flusso di cassa netto:
$546.00M
1 W Prestazione:
+6.92%
1M Prestazione:
-13.51%
6M Prestazione:
-46.16%
1 anno Prestazione:
-38.04%
Illumina Inc Stock (ILMN) Company Profile
Nome
Illumina Inc
Settore
Industria
Telefono
(858) 202-4500
Indirizzo
5200 ILLUMINA WAY, SAN DIEGO, CA
Confronta ILMN con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
ILMN
Illumina Inc
|
75.98 | 11.64B | 4.39B | -1.58B | 546.00M | -9.96 |
![]()
TMO
Thermo Fisher Scientific Inc
|
421.62 | 164.88B | 42.88B | 6.34B | 7.27B | 16.53 |
![]()
DHR
Danaher Corp
|
194.06 | 136.41B | 23.88B | 3.90B | 5.30B | 5.28 |
![]()
IDXX
Idexx Laboratories Inc
|
428.00 | 32.61B | 3.90B | 887.87M | 798.08M | 10.67 |
![]()
A
Agilent Technologies Inc
|
104.50 | 29.28B | 6.53B | 1.26B | 1.31B | 4.35 |
![]()
IQV
Iqvia Holdings Inc
|
146.96 | 26.17B | 15.41B | 1.37B | 2.11B | 7.50 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-03-04 | Reiterato | Citigroup | Neutral |
2025-02-28 | Downgrade | HSBC Securities | Buy → Hold |
2025-02-10 | Downgrade | Barclays | Equal Weight → Underweight |
2025-02-07 | Downgrade | TD Cowen | Buy → Hold |
2024-12-11 | Downgrade | Citigroup | Buy → Neutral |
2024-11-12 | Ripresa | Morgan Stanley | Equal-Weight |
2024-10-17 | Aggiornamento | HSBC Securities | Hold → Buy |
2024-08-28 | Aggiornamento | Argus | Hold → Buy |
2024-08-16 | Aggiornamento | Daiwa Securities | Neutral → Buy |
2024-08-14 | Aggiornamento | Barclays | Underweight → Equal Weight |
2024-08-14 | Aggiornamento | TD Cowen | Hold → Buy |
2024-07-10 | Aggiornamento | Citigroup | Neutral → Buy |
2024-06-03 | Ripresa | Jefferies | Hold |
2024-01-16 | Downgrade | HSBC Securities | Buy → Hold |
2024-01-04 | Downgrade | TD Cowen | Outperform → Market Perform |
2023-12-18 | Aggiornamento | Scotiabank | Sector Perform → Sector Outperform |
2023-12-15 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
2023-12-14 | Iniziato | Guggenheim | Buy |
2023-12-14 | Iniziato | Stephens | Overweight |
2023-12-13 | Iniziato | Wolfe Research | Outperform |
2023-12-12 | Downgrade | BofA Securities | Neutral → Underperform |
2023-12-11 | Aggiornamento | Citigroup | Sell → Neutral |
2023-11-10 | Downgrade | Canaccord Genuity | Buy → Hold |
2023-09-28 | Iniziato | Bernstein | Underperform |
2023-07-05 | Ripresa | JP Morgan | Neutral |
2023-01-25 | Downgrade | Argus | Buy → Hold |
2023-01-05 | Iniziato | Scotiabank | Sector Perform |
2022-12-12 | Downgrade | Citigroup | Neutral → Sell |
2022-12-07 | Iniziato | RBC Capital Mkts | Outperform |
2022-10-04 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
2022-09-28 | Aggiornamento | Evercore ISI | In-line → Outperform |
2022-08-25 | Iniziato | Credit Suisse | Neutral |
2022-07-13 | Downgrade | Barclays | Equal Weight → Underweight |
2022-01-18 | Aggiornamento | Stifel | Hold → Buy |
2022-01-11 | Aggiornamento | Barclays | Underweight → Equal Weight |
2022-01-07 | Aggiornamento | BofA Securities | Underperform → Neutral |
2022-01-06 | Ripresa | Morgan Stanley | Equal-Weight |
2022-01-06 | Ripresa | Piper Sandler | Overweight |
2021-10-15 | Ripresa | Cowen | Outperform |
2021-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
2021-06-01 | Aggiornamento | Evercore ISI | Underperform → In-line |
2021-03-31 | Downgrade | Atlantic Equities | Overweight → Neutral |
2021-03-31 | Aggiornamento | Canaccord Genuity | Hold → Buy |
2021-03-03 | Iniziato | Barclays | Underweight |
2020-12-22 | Aggiornamento | Piper Sandler | Neutral → Overweight |
2020-12-17 | Aggiornamento | BTIG Research | Neutral → Buy |
2020-10-13 | Downgrade | Guggenheim | Buy → Neutral |
2020-09-30 | Iniziato | Atlantic Equities | Overweight |
2020-09-29 | Downgrade | Wolfe Research | Outperform → Peer Perform |
2020-09-22 | Downgrade | Stifel | Buy → Hold |
2020-09-22 | Downgrade | UBS | Buy → Neutral |
2020-09-21 | Aggiornamento | Guggenheim | Neutral → Buy |
2020-09-21 | Downgrade | JP Morgan | Overweight → Neutral |
2020-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
2020-08-07 | Downgrade | Evercore ISI | In-line → Underperform |
2020-08-07 | Downgrade | Piper Sandler | Overweight → Neutral |
2020-07-07 | Downgrade | Guggenheim | Buy → Neutral |
2020-04-24 | Downgrade | Citigroup | Buy → Neutral |
2020-04-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
2020-01-08 | Iniziato | Wells Fargo | Underweight |
2020-01-07 | Iniziato | Citigroup | Buy |
2020-01-02 | Downgrade | Evercore ISI | Outperform → In-line |
2019-11-15 | Iniziato | Stifel | Buy |
2019-10-25 | Iniziato | Guggenheim | Buy |
Mostra tutto
Illumina Inc Borsa (ILMN) Ultime notizie
Should You Hold Illumina (ILMN)? - Yahoo Finance
Veraxa makes a SPAC deal; Illumina discloses layoffs - Endpoints News
Resmed Taps Illumina Exec for Chief Investor Relations Officer Role - Medical Product Outsourcing
Microarray Market Projected To Witness Massive Growth, 2025-2032 | Thermo Fisher Scientific Inc.,Illumina Inc. - openPR.com
DNA Microarray Technology Market: Innovations & Opportunities - openPR.com
Cancer Biopsy Market Detailed In New Research Report 2025 | - openPR.com
Genomic Cancer Testing Market Overall Study Report 2025-2032 | - openPR.com
Press Release Distribution & PR Platform - ACCESS Newswire
Thomas Kean Jr purchases shares in Illumina and nVent Electric - Investing.com Australia
Resmed Names Salli Schwartz as Chief Investor Relations Officer - The Manila Times
Resmed Names Salli Schwartz as Chief Investor Relations Officer - GlobeNewswire Inc.
Illumina, Inc. (ILMN): Among Recent Activist Investor Campaigns - Insider Monkey
Controlling Genes Market Detailed in New Research Report By 2032 - openPR.com
Illumina (ILMN) Receives a Buy from Leerink Partners - The Globe and Mail
Illumina, Tempus AI partner to drive genomic testing beyond cancer - MedTech Dive
Q4 Rundown: Illumina (NASDAQ:ILMN) Vs Other Life Sciences Tools & Services Stocks - Yahoo Finance
DNA Methylation Market Deep Research Report with Forecast by 2032 | Illumina, Inc.,Thermo Fisher Scientific - openPR.com
RNA Sequencing Market Size, Share, Outlook, Industry Analysis, - openPR.com
MicroRNA Market Size, Share, Trends, Opportunities, - openPR.com
AI in Omics Studies Market Overall Study Report 2025-2032 | Thermo Fisher Scientific, Agilent Technologies, Illumina - openPR.com
Illumina, Tempus AI To Collaborate To Accelerate Genomic AI Innovation - Nasdaq
Illumina and Tempus join forces to expand genomic testing By Investing.com - Investing.com India
Illumina, Tempus AI Collaborating to Accelerate Clinical Use of Sequencing Tests - marketscreener.com
Illumina And Tempus Partner To Drive The Future Of Precision Medicine Through Genomic Ai Innovation - MarketScreener
Illumina and Tempus join forces to expand genomic testing - Investing.com
Illumina and Tempus partner to drive the future of precision medicine through genomic AI innovation - PR Newswire
BofA Securities Cuts Price Target on Illumina to $75 From $90, Keeps Underperform Rating - MarketScreener
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Illumina, Inc.(ILMN) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Illumina (NASDAQ:ILMN) Price Target Cut to $112.00 by Analysts at Royal Bank of Canada - MarketBeat
Illumina : Welcomes Alex Aravanis as Chief Technology Officer and Appoints Mostafa Ronaghi to Lead Entrepreneurial Development - MarketScreener
Personalized Medicine Market Forecast Report and Company Analysis 2025-2033 Featuring Abbott, GE, Aadi Bioscience, Illumina, QIAGEN, Eli Lilly and Co, Takeda, AbbVie, F. Hoffmann-La RocheResearchAndMarkets.com | FinancialContent - FinancialContent
Illumina To Announce First Quarter 2025 Financial Results On Thursday, May 8, 2025 - MarketScreener
Shareholders in Illumina (NASDAQ:ILMN) have lost 77%, as stock drops 6.8% this past week - simplywall.st
Illumina to Announce First Quarter 2025 Financial Results on Thursday, May 8, 2025 - Yahoo Finance
Single-cell Omics Emerging Technologies and Markets Report 2025: 10x Genomics, Thermo Fisher & Illumina Lead $9.1 Billion Single-cell Omics Market by 2029 - Yahoo Finance
Cancer Profiling Market Positioned for Accelerated Growth with - openPR.com
Illumina (ILMN) Receives a Sell from Barclays - The Globe and Mail
Corvex’s Meister joins the board at Illumina. Here’s how he can create value for shareholders - MSN
Genotyping Assay Market Surges to USD 37.1 Billion by 2029: - openPR.com
Biotechnology company Illumina names Julie Hiner as comms head - Medical Marketing and Media
PacBio to cut jobs, lower spending over NIH funding cuts and tariffs - MarketScreener
DNA Data Storage Market to See Booming Growth 2025-2032 | Illumina, Inc.,Microsoft,Iridia, Inc.,Twist Bioscience - openPR.com
DNA Sequencing Technologies Market Deep Research Report with - openPR.com
Admera Health uses the NovaSeq X Plus to expand capabilities - Illumina
RBC Cuts Price Target on Illumina to $112 From $128, Keeps Outperform Rating - MarketScreener
Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - GlobeNewswire Inc.
Where are the Opportunities in (ILMN) - news.stocktradersdaily.com
Deep Dive Into Illumina Stock: Analyst Perspectives (14 Ratings) - Benzinga
Apple To $250? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
How Do Investors Really Feel About Illumina? - Benzinga
California Public Employees Retirement System Reduces Position in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Illumina Inc Azioni (ILMN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):